Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192296
Status:
COMPLETED
Last Update Posted:
2014-03-06
First Post:
2005-09-12
Brief Title:
Study to Evaluate the Safety TolerabilityImmunogenicity and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety TolerabilityImmunogenicity and Pharmacokinetics of MEDI-528 a Humanized Monoclonal Anti-Interleukin-9 Antibody in Healthy Adult Volunteers
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528
Detailed Description:
The primary objective of this Phase I study is to evaluate the safety and tolerability of escalating single IV doses of MEDI-528 administered to healthy adult volunteers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None